TRK-950 + nivolumab

TRK-950 + nivolumab is an investigational **combination therapy** under clinical evaluation for advanced solid tumors and several specific cancer types. **TRK-950** is a humanized monoclonal antibody targeting **CAPRIN-1** (Cell cycle-associated protein 1), a cell surface antigen that is highly expressed in many solid tumors. It works primarily by binding to CAPRIN-1 on tumor cells, potentially leading to their destruction via immune-mediated mechanisms such as antibody-dependent cellular cytotoxicity, and also shows promise as a component of radiopharmaceutical approaches for both imaging and therapy. **Nivolumab** is an approved monoclonal antibody that targets **programmed cell death protein 1 (PD-1)**, acting as a checkpoint inhibitor to enhance antitumor immune responses. The combination is in early-phase (Phase 1) clinical trials to evaluate safety, dosing, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors, including melanoma, ovarian cancer, gastric cancer, bladder cancer, renal cell carcinoma, and others, especially in settings refractory or resistant to prior therapy[1][3][5][7].